Cure Rare Disease Receives Orphan Drug Designation for SC3 Treatment

Strategic Insights -

Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational anti-sense oligonucleotide therapeutic for the treatment of Spinocerebellar Ataxia (SCA), including Spinocerebellar Ataxia Type 3 (SCA3). This designation acknowledges the significant unmet medical need within the SCA3 community and recognizes the potential of Cure Rare Disease's approach to provide a meaningful therapeutic benefit to affected individuals. The company's therapeutic approach offers a novel mechanism to slow or halt disease progression through targeted RNA-based modulation.

Key Takeaways:

  • Cure Rare Disease's investigational therapeutic, CRD-002, has been granted Orphan Drug Designation by the FDA for the treatment of Spinocerebellar Ataxia Type 3 (SCA3).
  • The FDA granted the designation due to the significant unmet medical need within the SCA3 community, which affects fewer than 200,000 individuals in the U.S.
  • CRD-002 is a single-stranded anti-sense oligonucleotide developed specifically to target the underlying cause of SCA3.
  • Cure Rare Disease's SCA3 program is being advanced through strong collaborative partnerships with Leiden University Medical Center, UCLA Medical Center, Charles River Laboratories, and Axolabs.
  • The company has received a $5.7 million grant from the California Institute for Regenerative Medicine (CIRM) to support the SCA3 program.
  • Cure Rare Disease is on track to complete IND-enabling studies and submit an IND to the FDA in 2026.

Statistics:

  • The FDA grants Orphan Drug Designation to investigational therapies addressing diseases affecting fewer than 200,000 individuals in the U.S (Source: FDA).
  • The designation provides tax credits for qualified clinical trials, exemption from certain FDA application fees, and eligibility for seven years of marketing exclusivity if the drug is approved (Source: FDA).
  • The California Institute for Regenerative Medicine (CIRM) awarded Cure Rare Disease a $5.7 million grant to support the SCA3 program.
  • The company has strong collaborative partnerships with multiple research institutions and laboratories to advance the SCA3 program.

Sources:

  • FDA (no specific citation or date provided)
  • FDA ( https://www.fda.gov/news-events/press-announcements/fda-grants-orphan-drug-designation-cure-rare-disease-s-sca3-program)
  • California Institute for Regenerative Medicine (CIRM) (no specific citation or date provided)